GW cannabis-derived epilepsy drug gets positive FDA staff review

LONDON (Reuters) – GW Pharmaceuticals’ cannabis-derived medicine for severe childhood epilepsy won a favorable review from U.S. Food and Drug Administration (FDA) staff on Tuesday, boosting hopes for its approval in the world’s biggest drugs market.

Source: Reuters Medical News

Leave a Reply

Your email address will not be published. Required fields are marked *